ChemDiv and Berlex Announce Collaboration
News Mar 13, 2006
ChemDiv, Inc. has announced that it has entered into a discovery research collaboration with Berlex Inc., a U.S. affiliate of Schering AG, Germany. The partners will work on the discovery of potential new lead compounds against several selected GPCR targets.
Under the terms of the collaboration, ChemDiv will apply its integrated synthetic and medicinal chemistry capabilities and collaborate with Berlex's scientists in the search for new disease therapies.
"We are looking forward to the opportunity to work with Berlex and view this as further validation of our discovery chemistry expertise," said Alexander Kiselyov, Executive VP of R&D at ChemDiv, Inc.
"ChemDiv's integrated drug discovery capabilities provide an excellent fit for Berlex and we hope that our collaborative relationship will be a long-standing one."
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE